The size of Sonic Healthcare's (ASX:SHL) acquisition of the LADR Laboratory Group Dr. Kramer & Colleagues in Germany raises antitrust issues that may force some divestitures, potentially impacting the economics of the acquisition, Jarden Research said in a Tuesday note.
Sonic Healthcare recently disclosed that it will acquire the laboratory testing services provider for 423 million euros and expects the acquisition to be immediately accretive to earnings per share.
The investment firm notes that the acquisition will increase the company's German revenue by about 34% in 2024, which is expected to increase in 2027 once the entire acquisition is complete.
The firm also believes that due to the size of this acquisition, the company is likely to "cap out" its ability to continue to acquire in Germany.
Jarden Research maintained its neutral rating on the company and raised its target price to AU$29.04 from AU$28.06.
Price (AUD): $28.34, Change: $+0.06, Percent Change: +0.21%
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。